# Individual Patient Compassionate Use of Crenolanib

> **NCT03620318** · — · AVAILABLE · sponsor: **Arog Pharmaceuticals, Inc.**

## Conditions studied

- FLT3-ITD Mutation
- FLT3/TKD Mutation
- PDGFR-Alpha D842V
- PDGFRA Gene Amplification

## Interventions

- **DRUG:** Crenolanib besylate

## Key facts

- **NCT ID:** NCT03620318
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03620318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03620318, "Individual Patient Compassionate Use of Crenolanib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03620318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*